AJTMH ASTMH MEMBERSHIP INFORMATION: astmh@astmh.org
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 62(2), 2000, pp. 271-276
Copyright © 2000 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Basco, L.
Right arrow Articles by Ringwald, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Basco, L.
Right arrow Articles by Ringwald, P
Related Collections
Right arrow Epidemiology
Right arrow Malaria
Right arrow Plasmodium
American Journal of Tropical Medicine and Hygiene, Vol 62, Issue 2, 271-276
Copyright © 2000 by American Society of Tropical Medicine and Hygiene

Research Articles


Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil

LK Basco and P Ringwald

Pyrimethamine and cycloguanil, the major human metabolite of proguanil, are inhibitors of dihydrofolate reductase that play a key role in the treatment and prevention of chloroquine-resistant Plasmodium falciparum infections in sub-Saharan Africa. Resistance to these antifolate drugs has emerged in some areas of Africa. Earlier molecular studies have demonstrated that point mutations at key positions of the dihydrofolate reductase-thymidylate synthase gene are strongly associated with antifolate resistance. However, whether the same or distinct mutations are involved in the development of resistance to both pyrimethamine and cycloguanil has not been well established in naturally occurring P. falciparum isolates. In this study, the in vitro responses to both antifolate drugs were measured in 42 Cameroonian isolates and compared with the complete sequence of the dihydrofolate reductase domain of the gene (from 34 of 42 isolates) to analyze the genotype that may distinguish between pyrimethamine and cycloguanil resistance. The wild-type profile (n = 11 isolates) was associated with low 50% inhibitory concentrations (IC50s) ranging from 0.32 to 21.4 nanamole for pyrimethamine and 0.60-6.40 nM for cycloguanil. Mutant isolates had at least one amino acid substitution, Asn-108. Only three mutant codons were observed among the antifolate-resistant isolates: Ile-51, Arg-59, and Asn-108. The increasing number of point mutations was associated with an increasing level of pyrimethamine IC50 and, to a much lesser extent, cycloguanil IC50. These results support a partial cross-resistance between pyrimethamine and cycloguanil that is based on similar amino acid substitutions in dihydrofolate reductase and suggest that two or three mutations, including at least Asn-108, may be necessary for cycloguanil resistance, whereas a single Asn-108 mutation is sufficient for pyrimethamine resistance.


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. M. McCollum, L. K. Basco, R. Tahar, V. Udhayakumar, and A. A. Escalante
Hitchhiking and Selective Sweeps of Plasmodium falciparum Sulfadoxine and Pyrimethamine Resistance Alleles in a Population from Central Africa
Antimicrob. Agents Chemother., November 1, 2008; 52(11): 4089 - 4097.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
R. Tahar and L. K. Basco
Molecular Epidemiology of Malaria in Cameroon. XXVI. Twelve-Year In Vitro and Molecular Surveillance of Pyrimethamine Resistance and Experimental Studies to Modulate Pyrimethamine Resistance
Am J Trop Med Hyg, August 1, 2007; 77(2): 221 - 227.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
R. TAHAR and L. K. BASCO
Molecular epidemiology of malaria in cameroon. Xxii. Geographic mapping and distribution of Plasmodium falciparum dihydrofolate reductase (dhfr) mutant alleles.
Am J Trop Med Hyg, September 1, 2006; 75(3): 396 - 401.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. L. Gatton, L. B Martin, and Q. Cheng
Evolution of Resistance to Sulfadoxine-Pyrimethamine in Plasmodium falciparum
Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2116 - 2123.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
L. K. BASCO
MOLECULAR EPIDEMIOLOGY OF MALARIA IN CAMEROON. XVII. BASELINE MONITORING OF ATOVAQUONE-RESISTANT PLASMODIUM FALCIPARUM BY IN VITRO DRUG ASSAYS AND CYTOCHROME B GENE SEQUENCE ANALYSIS
Am J Trop Med Hyg, August 1, 2003; 69(2): 179 - 183.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Aubouy, S. Jafari, V. Huart, F. Migot-Nabias, J. Mayombo, R. Durand, M. Bakary, J. Le Bras, and P. Deloron
DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy
J. Antimicrob. Chemother., July 1, 2003; 52(1): 43 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Wiesner, D. Henschker, D. B. Hutchinson, E. Beck, and H. Jomaa
In Vitro and In Vivo Synergy of Fosmidomycin, a Novel Antimalarial Drug, with Clindamycin
Antimicrob. Agents Chemother., September 1, 2002; 46(9): 2889 - 2894.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Society of Tropical Medicine and Hygiene.